GPCM
VYGR icon

Granite Point Capital Management’s Voyager Therapeutics VYGR Stock Holding History

Granite Point Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-65,000
Closed -$268K – 181
2021
Q2 		$268K Buy
+65,000
New +$295K 0.01% 149
2020
Q1 		– Sell
-17,650
Closed -$246K – 103
2019
Q4 		$246K Buy
+17,650
New +$257K 0.04% 78

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Granite Point Capital Management's VYGR Position: Q3 2021 in Review

Granite Point Capital Management sold out of Voyager Therapeutics (VYGR) in Q3 2021, closing a stake of 65,000 shares — an estimated $268K sold.

Granite Point Capital Management first reported a position in VYGR in Q4 2019 and held it in 2 quarters. The position peaked at $268K in Q2 2021. 69 funds tracked by Wall St. Rank hold VYGR as of Q3 2021.

  • Granite Point Capital Management reported no remaining Voyager Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Granite Point Capital Management sold 65,000 Voyager Therapeutics shares in Q3 2021, an estimated $268K.
  • Granite Point Capital Management first reported a position in Voyager Therapeutics in Q4 2019 and held it in 2 quarters.
  • Granite Point Capital Management's Voyager Therapeutics position peaked at $268K in Q2 2021.
  • 69 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2021.

Based on Granite Point Capital Management's 13F filing for Q3 2021, filed 10 Nov 2021.